Dilantin and Disease progression - a phase IV clinical study of FDA data

Summary:

Disease progression is reported as a side effect among people who take Dilantin (phenytoin sodium), especially for people who are female, 50-59 old, also take Decadron, and have Glioblastoma.

The phase IV clinical study analyzes which people have Disease progression when taking Dilantin. It is created by eHealthMe based on reports of 19,857 people who have side effects when taking Dilantin from the FDA, and is updated regularly.

What is Dilantin?

Dilantin has active ingredients of phenytoin sodium. It is often used in epilepsy. eHealthMe is studying from 20,858 Dilantin users. Check the latest studies of Dilantin.

What is Disease progression?

Disease progression is found to be associated with 1,802 drugs and 2,253 conditions by eHealthMe. Check the latest studies of Disease progression.

On Jul, 08, 2026

19,857 people reported to have side effects when taking Dilantin.
Among them, 152 people (0.77%) have Disease progression.

Could Dilantin cause Disease progression?

Among these 152 people:

What is the gender of people who have Disease progression when taking Dilantin? *

Click here to view

* Approximation only. Some reports may have incomplete information.

Do you take Dilantin and have Disease progression?

- Check whether Disease progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dilantin:

Dilantin (20,858 reports)

Disease progression treatments and more:

Disease progression (115,298 reports)

How severe was Disease progression and when was it recovered:

Disease progression in Dilantin

Expand to all the drugs that have ingredients of phenytoin sodium:

Disease progression and drugs with ingredients of phenytoin sodium

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Dilantin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Disease progression:

Disease progression (1,802 drugs)

Browse all the conditions that are associated with Disease progression:

Disease progression (2,253 conditions)

Related publications that referenced our studies

Akasaka E, Kayo SJ, Nakano H, Ishii N, Hashimoto T, Sawamura D, "Diaminodiphenyl Sulfone-Induced Hemolytic Anemia and Alopecia in a Case of Linear IgA Bullous Dermatosis", Case reports in dermatology, 2014 Jan .
Akasaka E, Kayo SJ, Nakano H, Ishii N, Hashimoto T, Sawamura D, "Diaminodiphenyl Sulfone-Induced Hemolytic Anemia and Alopecia in a Case of Linear IgA Bullous Dermatosis", Case reports in dermatology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on phenytoin sodium (the active ingredients of Dilantin) and Dilantin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.